These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29044544)

  • 21. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 22. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
    Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
    JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
    Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
    Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
    Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
    J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
    [No Abstract]   [Full Text] [Related]  

  • 30. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
    Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
    Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
    Yao L; Tang C; Feng W; Dai H
    Med Sci Monit; 2022 Jun; 28():e937136. PubMed ID: 35718990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
    Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
    BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
    Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
    World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
    Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
    Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
    BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.